Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Curr Oncol Rep. 2020 Aug 15;22(11):111. doi: 10.1007/s11912-020-00973-0.
Cancer remains a major cause of morbidity and mortality in HIV-infected individuals, with aggressive non-Hodgkin's lymphoma as the most frequent one. However, the introduction of modern antiretroviral therapy (ART) drastically improved treatment options and prognosis in HIV-associated lymphomas. This review summarized the current treatment landscape and future challenges in HIV-positive patients with non-Hodgkin's and Hodgkin's lymphoma.
Selecting the appropriate therapy for the individual patient, diffuse-large B cell lymphoma, Burkitt's lymphoma, and Hodgkin's disease may be curable diseases. In contrast, the prognosis of plasmablastic lymphoma and primary effusion lymphoma remain poor. New treatment approaches, as targeted therapies or CAR T cell therapy, may broaden the therapeutic armamentarium. The continuous application of ART is mandatory for successful treatment. The choice of lymphoma therapy may follow the recommendations for HIV-negative patients, but prospective trials in HIV-lymphoma are needed.
癌症仍然是 HIV 感染者发病和死亡的主要原因，侵袭性非霍奇金淋巴瘤是最常见的原因。然而，现代抗逆转录病毒疗法（ART）的引入极大地改善了 HIV 相关淋巴瘤的治疗选择和预后。本综述总结了 HIV 阳性非霍奇金淋巴瘤和霍奇金淋巴瘤患者的当前治疗现状和未来挑战。
对于个体患者，选择适当的治疗方法，弥漫性大 B 细胞淋巴瘤、伯基特淋巴瘤和霍奇金病可能是可治愈的疾病。相比之下，浆母细胞淋巴瘤和原发性渗出性淋巴瘤的预后仍然较差。新的治疗方法，如靶向治疗或嵌合抗原受体 T 细胞疗法，可能会扩大治疗手段。连续应用 ART 是成功治疗的必要条件。淋巴瘤治疗的选择可以遵循针对 HIV 阴性患者的建议，但需要进行前瞻性的 HIV 淋巴瘤试验。
